183 related articles for article (PubMed ID: 34536546)
21. NSD1: A Lysine Methyltransferase between Developmental Disorders and Cancer.
Tauchmann S; Schwaller J
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575025
[TBL] [Abstract][Full Text] [Related]
22. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
23. The NSD1 and EZH2 overgrowth genes, similarities and differences.
Tatton-Brown K; Rahman N
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):86-91. PubMed ID: 23592277
[TBL] [Abstract][Full Text] [Related]
24. H3K36 methyltransferase NSD1 is essential for normal B1 and B2 cell development and germinal center formation.
Zhai S; Cao M; Zhou H; Zhu H; Xu T; Wang Y; Wang X; Cai Z
Front Immunol; 2022; 13():959021. PubMed ID: 36532012
[TBL] [Abstract][Full Text] [Related]
25. Understanding the language of Lys36 methylation at histone H3.
Wagner EJ; Carpenter PB
Nat Rev Mol Cell Biol; 2012 Jan; 13(2):115-26. PubMed ID: 22266761
[TBL] [Abstract][Full Text] [Related]
26. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2.
Amin N; Nietlispach D; Qamar S; Coyle J; Chiarparin E; Williams G
Biomol NMR Assign; 2016 Oct; 10(2):315-20. PubMed ID: 27356987
[TBL] [Abstract][Full Text] [Related]
27. Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1.
Sun Z; Lin Y; Islam MT; Koche R; Hedehus L; Liu D; Huang C; Vierbuchen T; Sawyers CL; Helin K
Mol Cell; 2023 Jul; 83(14):2398-2416.e12. PubMed ID: 37402365
[TBL] [Abstract][Full Text] [Related]
28. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
29. NSD1 is essential for early post-implantation development and has a catalytically active SET domain.
Rayasam GV; Wendling O; Angrand PO; Mark M; Niederreither K; Song L; Lerouge T; Hager GL; Chambon P; Losson R
EMBO J; 2003 Jun; 22(12):3153-63. PubMed ID: 12805229
[TBL] [Abstract][Full Text] [Related]
30. Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
Krossa I; Strub T; Aplin AE; Ballotti R; Bertolotto C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230787
[TBL] [Abstract][Full Text] [Related]
31. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
32. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
33. Histone lysine methyltransferase SET8 is a novel therapeutic target for cancer treatment.
Yang C; Wang K; Zhou Y; Zhang SL
Drug Discov Today; 2021 Oct; 26(10):2423-2430. PubMed ID: 34022460
[TBL] [Abstract][Full Text] [Related]
34. Histone methylation mediated by NSD1 is required for the establishment and maintenance of neuronal identities.
Zheng Y; Zhao C; Song Q; Xu L; Zhang B; Hu G; Kong X; Li S; Li X; Shen Y; Zhuang L; Wu M; Liu Y; Zhou Y
Cell Rep; 2023 Dec; 42(12):113496. PubMed ID: 37995181
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation analysis of multiple imprinted DMRs in Sotos syndrome reveals IGF2-DMR0 as a DNA methylation-dependent, P0 promoter-specific enhancer.
Watanabe H; Higashimoto K; Miyake N; Morita S; Horii T; Kimura M; Suzuki T; Maeda T; Hidaka H; Aoki S; Yatsuki H; Okamoto N; Uemura T; Hatada I; Matsumoto N; Soejima H
FASEB J; 2020 Jan; 34(1):960-973. PubMed ID: 31914674
[TBL] [Abstract][Full Text] [Related]
36. A sensitive luminescent assay for the histone methyltransferase NSD1 and other SAM-dependent enzymes.
Drake KM; Watson VG; Kisielewski A; Glynn R; Napper AD
Assay Drug Dev Technol; 2014 Jun; 12(5):258-71. PubMed ID: 24927133
[TBL] [Abstract][Full Text] [Related]
37. NSD1 promotes esophageal cancer tumorigenesis via HIF1α signaling.
He F; Xiao H; Cai Y; Zhang N
Cell Biol Toxicol; 2023 Aug; 39(4):1835-1850. PubMed ID: 36522543
[TBL] [Abstract][Full Text] [Related]
38. NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.
Nakshatri H; Appaiah HN; Anjanappa M; Gilley D; Tanaka H; Badve S; Crooks PA; Mathews W; Sweeney C; Bhat-Nakshatri P
Cell Death Dis; 2015 Jan; 6(1):e1608. PubMed ID: 25611383
[TBL] [Abstract][Full Text] [Related]
39. Investigating cortical features of Sotos syndrome using mice heterozygous for Nsd1.
Oishi S; Zalucki O; Vega MS; Harkins D; Harvey TJ; Kasherman M; Davila RA; Hale L; White M; Piltz S; Thomas P; Burne THJ; Harris L; Piper M
Genes Brain Behav; 2020 Apr; 19(4):e12637. PubMed ID: 31909872
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
